Cronos GroupCRON +3.42%86 Quick Ratio is 20.73 as of Mar. 2026, which is 43% above its 10-year median of 14.47. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.54 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 995 Drug Manufacturers companies, Cronos Group ranks better than 98.19% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Cronos Group's quick ratio for the quarter that ended in Mar. 2026 was 20.73.
Cronos Group has a quick ratio of 20.73. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cronos Group's Quick Ratio or its related term are showing as below:
CRON'
s Quick Ratio Range Over the Past 10 Years
Min: 0.56 Med: 14.47 Max: 44.51
Current: 20.73
During the past 12 years, Cronos Group's highest Quick Ratio was 44.51. The lowest was 0.56. And the median was 14.47.
CRON's Quick Ratio is ranked better than 98.19% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs CRON: 20.73
Cronos Group (NAS:CRON) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cronos Group Quick Ratio Related Terms
Cronos Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cronos Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cronos Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cronos Group's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a Quick Ratio of 20.73 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cronos Group and its competitors. This is 43% above median its historical median of 14.47. Over the past decade, Cronos Group's Quick Ratio has ranged from 0.56 to 44.51. According to the industry distribution chart, Cronos Group ranks #18 out of 995 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Cronos Group's Quick Ratio too high?
Cronos Group's current Quick Ratio of 20.73 is 43% above median its 10-year median of 14.47. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 44.51. The Drug Manufacturers industry median Quick Ratio is 1.45. Cronos Group's value of 20.73 is 1329.7% above this industry median. Based on the distribution chart, Cronos Group ranks #18 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #18 out of 995 companies for Quick Ratio. This places Cronos Group in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Cronos Group's value of 20.73 is 1329.7% above this benchmark. Historically, Cronos Group's own Quick Ratio has ranged from 0.56 to 44.51 over the past decade. While the company's 10-year median is 14.47 vs. the industry median of 1.45, Cronos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Quick Ratio of 20.73 is 1329.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Quick Ratio is 20.73, which is 43% above median its own 10-year median of 14.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.54, compared to a current price of $2.88 — trading 18.8% below its estimated fair value. The current Quick Ratio is 20.73, which is 43% above median its 10-year median of 14.47 and 1329.7% above the Drug Manufacturers industry median of 1.45. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cronos Group (CRON), the current Quick Ratio is 20.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.88 is trading 18.8% below its estimated GF Value™ of $3.54.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
Quick Ratio: 20.73 (43% above median its 10-year median of 14.47)
GF Value™: $3.54 vs. price of $2.88 (18.8% below fair value)
Industry Position: 1329.7% above the Drug Manufacturers median (#18 of 995)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
